Association of the previously published matrix determinants with RRP status on univariate and multivariate analysis
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| RRP+ (n=41) | RRP− (n=329) | p Value | Estimate | SE | p Value | |
| ESPOIR matrix | ||||||
| Swollen joint count 14–20 | 6 (14.6) | 32 (9.7) | 0.08 | 0.28 | 0.53 | 0.60 |
| Swollen joint count >20 | 4 (9.8) | 12 (3.7) | 1.25 | 0.68 | 0.07 | |
| CRP<35 mg/L | 25 (61.0) | 168 (51.1) | 0.04 | 0.83 | 0.57 | 0.15 |
| CRP ≥35 mg/L | 12 (29.3) | 72 (21.9) | 0.86 | 0.63 | 0.17 | |
| ACPA positivity | 31 (75.6) | 154 (46.8) | 0.0007 | 1.11 | 0.40 | 0.006 |
| Typical RA erosion | 18 (43.9) | 48 (14.6) | <0.0001 | 1.31 | 0.37 | 0.0004 |
| mESPOIR matrix | ||||||
| Swollen joint count >13 | 10 (24.4) | 44 (13.4) | 0.09 | 0.89 | 0.46 | 0.05 |
| ACPA positivity | 31 (75.6) | 154 (46.8) | 0.0007 | 1.22 | 0.41 | 0.003 |
| Baseline SHS 5–14 | 19 (46.3) | 48 (14.6) | <0.0001 | 2.15 | 0.41 | <0.0001 |
| Baseline SHS>14 | 10 (24.4) | 18 (5.5) | 2.34 | 0.51 | <0.0001 | |
| SONORA matrix | ||||||
| DAS28≤3.2 | 2 (4.9) | 14 (4.3) | 0.69 | 0.41 | 0.87 | 0.64 |
| ACPA≤20 UI/L | 10 (24.4) | 170 (51.7) | 0.001 | −1.09 | 0.40 | 0.007 |
| Baseline vSHS=0 | 3 (7.3) | 112 (34.0) | <0.0001 | −2.80 | 0.67 | <0.0001 |
| Baseline vSHS=1–5 | 9 (21.9) | 151 (45.9) | −1.97 | 0.47 | <0.0001 | |
| Baseline vSHS=6–10 | 13 (31.7) | 32 (9.7) | −0.06 | 0.46 | 0.90 | |
| ASPIRE matrix | ||||||
| Swollen joint count 10–17 | 11 (26.8) | 79 (24.0) | 0.72 | 0.25 | 0.40 | 0.54 |
| Swollen joint count ≥17 | 4 (9.8) | 26 (7.9) | 0.45 | 0.60 | 0.45 | |
| CRP 6–30 mg/L | 21 (51.2) | 134 (40.7) | 0.09 | 0.92 | 0.48 | 0.06 |
| CRP≥30 mg/L | 13 (31.7) | 84 (25.5) | 1.41 | 0.61 | 0.02 | |
| ESR 21–50 mm/1st h | 18 (43.9) | 107 (32.5) | 0.37 | −0.07 | 0.42 | 0.86 |
| ESR ≥50 mm/1st h | 8 (19.5) | 81 (24.6) | −1.03 | 0.60 | 0.09 | |
| RF 80–200 UI | 6 (14.6) | 23 (7.0) | 0.02 | 1.08 | 0.52 | 0.04 |
| RF≥200 UI | 10 (24.4) | 42 (12.8) | 0.97 | 0.43 | 0.02 | |
| BEST matrix | ||||||
| CRP 10–35 mg/L | 13 (31.7) | 108 (32.8) | 0.55 | 0.03 | 0.43 | 0.95 |
| CRP≥35 mg/L | 12 (29.3) | 72 (21.9) | 0.11 | 0.44 | 0.81 | |
| RF+ or ACPA+ | 4 (9.8) | 51 (15.5) | 0.007 | 0.05 | 0.65 | 0.94 |
| RF+ and ACPA+ | 28 (68.3) | 139 (42.2) | 0.94 | 0.43 | 0.03 | |
| Radiographic erosions 1–3 | 8 (19.5) | 123 (37.4) | <0.0001 | 0.75 | 0.63 | 0.23 |
| Radiographic erosions ≥4 | 29 (70.7) | 73 (22.2) | 2.48 | 0.56 | <0.0001 | |
| SWEFOT matrix | ||||||
| Current smoker | 14 (34.1) | 158 (48.0) | 0.09 | −0.51 | 0.36 | 0.15 |
| CRP 10–35 mg/L | 13 (31.7) | 108 (32.8) | 0.55 | 0.03 | 0.41 | 0.94 |
| CRP≥35 mg/L | 12 (29.3) | 72 (21.9) | 0.32 | 0.42 | 0.46 | |
| Radiographic erosions | 18 (43.9) | 48 (14.6) | <0.0001 | 1.47 | 0.35 | <0.0001 |
ACPA, anti-citrullinated protein antibody; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor; RRP, rapid radiographic progression; vSHS, van der Heijde-modified Sharp score.